News & Events about Arvinas Inc.
NEW HAVEN, Conn., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Brad Margus, M.B.A., has stepped down from the companys Board and Everett Cunningham has ...
Arvinas, Inc. (NASDAQ:ARVN Get Rating) has earned an average rating of Moderate Buy from the seventeen analysts that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and eleven have assigned a buy ...
Arvinas (NASDAQ:ARVN Get Rating) had its target price decreased by Cantor Fitzgerald from $106.00 to $90.00 in a report issued on Wednesday morning, The Fly reports. Several other analysts have also recently commented on ARVN. Morgan Stanley reduced their target price on shares of Arvinas from $63....
Globe Newswire
2 months ago
ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free survival of 3.7 months in all patients and 5.7 months in patients with ESR1 mutant tumors support the initiation of two Phase 3 registrational trials...